News & Events
Miami Cancer Institute Implements Philips Precision Medicine Genomics Platform
NEW YORK (GenomeWeb) – The Miami Cancer Institute has signed a multiyear agreement to use Royal Philips' IntelliSpace Precision Medicine Genomics software platform in its new genomics laboratory.
The partnership, announced today, will support the oncology genomic testing workflow at the institute, which is part of Baptist Health South Florida. It also helped the institute launch Illumina TruSight Tumor 170 (TST170), a sequencing panel test that targets SNVs, gene amplifications, gene fusions, and splice variants found in 170 cancer-related genes.
For the TST170 panel, the IntelliSpace platform is providing data capture and storage of variants, annotations, clinical interpretation, and treatment recommendations, according to Amsterdam-based Philips.
"With the implementation of this system, Miami Cancer Institute is among a small number of elite cancer programs across the globe to bring all aspects of precision medicine under one roof," Jeff Boyd, the institute's associate deputy director for translational research, said in a statement.
"By leveraging this solution from Philips, we can provide our oncology care teams with the information they need to make better care decisions, helping our institution deliver on our mission to provide the highest clinical quality possible," added Qi Wei, director of Miami Cancer Institute's genomics lab service.